Upadacitinib combined with narrowband ultraviolet B for nonsegmental vitiligo: a single-centre prospective study
Clinical and Experimental Dermatology · 12.10.2026
DOI: 10.1093/ced/llag437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 12.10.2026. Verfasst von Lu Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chin…. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Beijing Key Clinical Specialty Construction Project, Fundamental Research Funds for Central Universities.
Abstract (Originalsprache)
Background
Vitiligo is a chronic autoimmune depigmenting disorder. Limited therapeutic options exist for patients with active and refractory disease. Janus kinase (JAK) inhibitors have emerged as promising treatments, and combination with phototherapy may further enhance repigmentation.
Objectives
To evaluate the efficacy and safety of oral upadacitinib combined with narrowband ultraviolet B (NB-UVB) phototherapy in patients with active nonsegmental vitiligo.
Methods
In this prospective cohort study, adults with active nonsegmental vitiligo and inadequate response to prior therapies received either oral upadacitinib (15 mg once daily) combined with NB-UVB phototherapy or NB-UVB alone for 12 weeks. The primary endpoint was achievement of ≥ 50% improvement in total Vitiligo Area Scoring Index (T-VASI 50) at week 12. Secondary endpoints included changes in T-VASI, facial VASI, Vitiligo Extent Score (VES) and disease activity and improvement scores (Vitiligo Disease Activity Score and Vitiligo Disease Improvement Score). Safety was assessed throughout the study.
Results
In total, 38 patients were included, with 19 patients in each treatment group. At week 12, 47% of patients (9 of 19) in the combination group achieved T-VASI 50, compared with 5% (1 of 19) in the NB-UVB monotherapy group (P = 0.008). The combination group showed significantly greater mean percentage improvements in T-VASI (mean 49.1%, SD 20.3 vs. mean 18.7%, SD 14.3; P < 0.01) and VES (mean 44.6%, SD 20.1 vs. mean 18.6%, SD 13.8; P < 0.01). Superior responses were observed in truncal and nonacral extremity lesions, whereas facial outcomes did not differ significantly between groups. All adverse events were mild, and no serious adverse events were reported.
Conclusions
Oral upadacitinib combined with NB-UVB phototherapy demonstrated superior short-term efficacy compared with NB-UVB alone in patients with active nonsegmental vitiligo, with an acceptable safety profile. These findings support this combination as a promising therapeutic strategy and warrant further validation in larger randomized controlled trials with longer follow-up.
Autor:innen und Institutionen
- Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
ORCID-Profile: Tao Wang
Förderung
- Beijing Key Clinical Specialty Construction Project
- Fundamental Research Funds for Central Universities
Zitieren
APA
Lu, L., Feng, J., Yang, L., He, H., Peng, Y., Xie, A., Zhang, S., Liu, Y., & Wang, T. (2026). Upadacitinib combined with narrowband ultraviolet B for nonsegmental vitiligo: a single-centre prospective study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag437
Vancouver
Lu L, Feng J, Yang L, He H, Peng Y, Xie A, et al. Upadacitinib combined with narrowband ultraviolet B for nonsegmental vitiligo: a single-centre prospective study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag437
BibTeX
@article{Lu2026,
author = {Lu, Lu and Feng, Jindi and Yang, Lu and He, Huimin and Peng, Yubin and Xie, Anqi and Zhang, Shiyu and Liu, Yuehua and Wang, Tao},
title = {Upadacitinib combined with narrowband ultraviolet B for nonsegmental vitiligo: a single-centre prospective study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag437}
}
EUVIMED